NASDAQ:BTAI | Free Cash Flow | BioXcel Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2017-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$11.81M$0.00-$11.81M
2025-12-31-$14.21M$0.00-$14.21M
2025-03-31-$12.04M$0.00-$12.04M
2024-12-31-$14.81M$0.00-$14.81M
2024-03-31-$17.71M
2023-12-31-$26.86M$0.00-$26.86M
2023-03-31-$52.35M
2022-12-31-$38.64M$0.00-$38.64M
2022-03-31-$32.41M$120,000.00-$32.53M
2021-12-31-$19.93M$12,000.00-$19.94M
2021-03-31-$19.64M$316,000.00-$19.96M
2020-12-31-$20.27M$270,000.00-$20.54M
2020-03-31-$12.16M$16,000.00-$12.17M
2019-12-31-$7.92M$2,000.00-$7.92M
2019-03-31-$5.67M$600,000.00-$6.27M
2018-12-31-$4.34M$158,000.00-$4.5M
2018-03-31-$1.01M
2017-12-31-$1.1M
2017-03-31-$431,000.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$57.62M$0.00-$57.62M
2024-12-31-$72.03M$0.00-$72.03M
2023-12-31-$155.01M$20,000.00-$155.03M
2022-12-31-$135.34M$139,000.00-$135.48M
2021-12-31-$82.15M$445,000.00-$82.6M
2020-12-31-$66.35M$316,000.00-$66.67M
2019-12-31-$27.1M$870,000.00-$27.97M
2018-12-31-$13.51M$340,000.00-$13.85M
2017-12-31-$2.2M